跳至主要内容
临床试验/NCT00762775
NCT00762775已完成不适用

The Interaction Between Calcium and Vitamin D Intake

Winthrop University Hospital1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2008年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
78
试验地点
1
主要终点
The influence of calcium supplementation alone on serum PTH levels and bone markers in healthy adult women.

研究概览

简要总结

We will study the relative importance of high calcium intake and vitamin D supplementation for calcium homeostasis, as determined by serum parathyroid hormone (PTH) and biochemical bone markers. We also intend to examine the interaction of vitamin D and calcium intake on calcium homeostasis. We hypothesize that optimal calcium supplementation and optimal vitamin D supplementation will lead to lower serum levels of PTH and markers of bone resorption compared with the placebo. We also theorize that when taken together, optimal calcium supplementation and optimal vitamin D intake will result in lower serum levels of PTH and bone markers compared with calcium or vitamin D taken alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
45 Years 至 85 Years(Adult, Older Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Healthy women aged 45 and above who have been menopausal at least 1 year (absence of menstrual period for a period of 12 months or more)

排除标准

  • •Any chronic medical illness including uncontrolled diabetes mellitus, recent history of myocardial infarction, or heart failure, malignancy, uncontrolled hypertension, obesity (BMI>35 kg/m2), history of anemia, leukemia, or other hematologic abnormalities, lupus, rheumatoid arthritis, or other rheumatologic disease, or kidney disease of any kind as determined by history and physical examination.
  • •Subjects with osteoporosis of the hip (total hip T-score equal or less than -2.5) or taking medications for osteoporosis such as bisphosphonates will be excluded.
  • •Pregnancy.
  • •Use of medication that influences bone metabolism (i.e. anticonvulsant medications, chronic use of steroids and high dose diuretics).
  • •Significant deviation from normal in medical history, physical examination, or laboratory tests as evaluated by the primary investigator.
  • •Patients with a history of hypercalciuria, hypercalcemia, nephrolithiasis, and active sarcoidosis will also be excluded.
  • •Participation in another investigational trial in the past 30 days prior to the screening evaluation.
  • •Unexplained weight loss of >15% during the previous year or history of anorexia nervosa.
  • •Medications that interfere with vitamin D metabolism.
  • •Patients with a habitual dietary calcium intake that exceeds 800 mg/day.
  • •Smokers greater than 1 pack per day will be excluded.
  • •Patients reporting alcohol intake greater than 2 drinks daily.
  • •Serum 25-hydroxyvitamin D level > 75 nmol/L.

研究组 & 干预措施

1

Experimental

Calcium supplementation and placebo

干预措施: Calcium and vitamin D supplementation (Dietary Supplement)

2

Experimental

Vitamin D supplementation and placebo

干预措施: Calcium and vitamin D supplementation (Dietary Supplement)

3

Experimental

Calcium and Vitamin D supplementation

干预措施: Calcium and vitamin D supplementation (Dietary Supplement)

4

Placebo Comparator

Placebos only

干预措施: Calcium and vitamin D supplementation (Dietary Supplement)

结局指标

主要结局

The influence of calcium supplementation alone on serum PTH levels and bone markers in healthy adult women.

时间窗: 6 months

次要结局

  • The interaction between calcium and vitamin D supplementation and their combined effect on serum PTH hormone levels and bone markers in healthy adult women.(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

John F. Aloia, MD

Principal Investigator

Winthrop University Hospital

研究点 (1)

Loading locations...

相似试验